Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maltosyl-alpha (1,4)-D-Gluconhydroximo-1,5-Lactam is a synthetic small molecule belonging to the class of o-glycosyl compounds and glycoconjugates[1][2][4]. It is structurally characterized as a complex carbohydrate derivative with the molecular formula C18H32N2O15[2][6]. This compound has been studied primarily as an experimental inhibitor of pancreatic alpha-amylase—a key enzyme involved in starch digestion—by binding to its active site and blocking enzymatic activity[8][10]. Its mechanism of action involves competitive inhibition of alpha-amylase activity. The compound has not been approved for clinical use and remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maltosyl-alpha (1,4)-d-gluconhydroximo-1,5-lactam.